Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, ...

Researchers at Acadia University find that wine drinkers are more accepting of pasta sauce formulated with the addition of grape pomace than those who do not drink wine.

There's a lot of buzz about GMO food out there, and much of it is false. We're here to bust some common misconceptions and ...

Analyst Josh Jennings of TD Cowen maintained a Buy rating on Humacyte (HUMA – Research Report), retaining the price target of $10.00.Don't Miss ...

United Therapeutics is a leader in PAH treatments, with Tyvaso being the primary revenue driver. Check out why I rate UTHR ...

Bioengineered Food Global Market Report 2024 : Market Size, Trends, And Global Forecast 2024-2033 Bioengineered Food Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033 The.

DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, ...

Humacyte, a Durham-based regenerative medicine company, has begun a Phase 2 clinical trial of Humacyl, its bioengineered blood vessel, in patients with vascular trauma. The study will evaluate Humacyl ...

The Kobe University bioengineer Hasunuma Tomohisa says, "To obtain a high-yield and low-cost supply, it is desirable to produce it in bioengineered microorganisms which can be grown in fermenters." ...